The partners are also working together to validate the company's molecular testing technologies in various settings.

The firm revised its revenue guidance for full-year 2026 to a range of $802 million to $806 million, and its net loss for the year to a range of $42 million to $34 million.

The platform combines machine learning and sample preparation techniques with the firm's proprietary Raman spectral databases.

HHS OIG issued five recommendations, including refunding the federal government $18.5 million, as well as additional refunds for other potential overpayments.